Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab dose-escalation and expansion study in relapsed or refractory B-cell lymphoma
NL-OMON54761Phase 2Recruiting
- Sponsor
- Genmab
- Start
- Jul 2018
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in mature B-cell lymphoma, non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and 6 more (5 arms), sponsored by Genmab. Primary endpoints: Dose-limiting toxicity, Adverse events and 2 more. Started Jul 2018; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
mature B-cell lymphomanon-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NL-OMON54761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54761.